Evolus' competitive position has shifted: Jeuveau (prabotulinumtoxinA) is now the company's primary growth driver and margin engine, eclipsing the legacy device business (Evoke RF). The injectable platform—built on Evolus Rewards rebate program and direct-to-practice relationships—is generating the predictable, recurring revenue that investors value in toxin franchises.
Injectables
Evolus' Injectable Platform Is Becoming Its Real Moat
Jeuveau's market share gains and pricing power signal toxin portfolio is outpacing device legacy.
1-YEAR MOVE
EOLS
▼15.6%
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| EOLS | Evolus | −15.6% |
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Injectable platform now the real moat, outpacing legacy device business.
For practice owners, this is significant. Evolus has moved from a device-first strategy to a toxin-first strategy, meaning the company's pricing, rebate terms, and market focus will increasingly mirror AbbVie and Galderma. Jeuveau's gain in market share reflects both aggressive rebate stacking and clinical parity with BOTOX—and Evolus' willingness to sacrifice device margin to own the toxin relationship. Watch for continued pressure on Jeuveau per-unit economics as the company scales.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.